Unknown

Dataset Information

0

Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours.


ABSTRACT: The aim of this phase 1, single centre, open label study in four patients with solid tumours was to determine the absolute bioavailability of a 2?mg oral dose of trametinib. Trametinib is an orally bioavailable, reversible and selective allosteric inhibitor of MEK1 and MEK2 activation and kinase activity.A microtracer study approach, in which a 5??g radiolabelled i.v. microdose of trametinib was given concomitantly with an unlabelled 2?mg oral tablet formulation, was used to recover i.v. and oral pharmacokinetic parameters, simultaneously.The least-squares mean (90% confidence interval) absolute bioavailability of trametinib (2?mg tablet) was 72.3% (50.0%, 104.6%). Median tmax after oral administration was 1.5?h and the geometric mean terminal half-life was 11?days. The geometric mean clearance and volume of distribution after i.v. administration were 3.21?l?h(-1) and 976?l, respectively, resulting in a terminal elimination half-life of 11?days.Trametinib absolute bioavailability was moderate to high, whereas first pass metabolism was low.

SUBMITTER: Leonowens C 

PROVIDER: S-EPMC4243903 | biostudies-literature | 2014 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours.

Leonowens Cathrine C   Pendry Carolyn C   Bauman John J   Young Graeme C GC   Ho May M   Henriquez Frank F   Fang Lei L   Morrison Royce A RA   Orford Keith K   Ouellet Daniele D  

British journal of clinical pharmacology 20140901 3


<h4>Aims</h4>The aim of this phase 1, single centre, open label study in four patients with solid tumours was to determine the absolute bioavailability of a 2 mg oral dose of trametinib. Trametinib is an orally bioavailable, reversible and selective allosteric inhibitor of MEK1 and MEK2 activation and kinase activity.<h4>Methods</h4>A microtracer study approach, in which a 5 μg radiolabelled i.v. microdose of trametinib was given concomitantly with an unlabelled 2 mg oral tablet formulation, was  ...[more]

Similar Datasets

| S-EPMC9794608 | biostudies-literature
| S-EPMC5520097 | biostudies-literature
| S-EPMC3579265 | biostudies-literature
| S-EPMC6288157 | biostudies-literature
| S-EPMC4109286 | biostudies-literature
| S-EPMC4430599 | biostudies-literature
| S-EPMC4541973 | biostudies-literature
| S-EPMC8604249 | biostudies-literature
| S-EPMC7574157 | biostudies-literature
| S-EPMC7318034 | biostudies-literature